

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

FFW  
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Filing Receipt Corrections, Office of Initial Patent Examination, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Receipt  
LUD 5684.2 CIP (10106926)

Filed: 5/16/04 Signature: Jani Malikouzakis (Jani Malikouzakis)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of: Jean-Christophe RENAULD et al.

Application No.: 09/919,162

Group Art Unit: 1645

Filed: July 31, 2001

Examiner: UNKNOWN

For: ISOLATED NUCLEIC ACID MOLECULES WHICH  
ENCODE A SOLUBLE IL-TIF RECEPTOR OR  
BINDING PROTEIN WHICH BINDS TO IL-TIF/IL-22,  
AND USES THEREOF

**REQUEST FOR CORRECTED FILING RECEIPT**

Filing Receipt Corrections  
Office of Initial Patent Examination  
Commissioner for Patents, P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Applicant hereby requests that a corrected Filing Receipt be issued in the above-identified patent application. The official Filing Receipt received by Applicant, a copy of which is attached hereto, has the following error(s):

In the APPLICANTS section of the Filing Receipt, the second named inventor's name is incorrect. The correct spelling is --  
**Laure DUMOUTIER** --. Please see the attached executed Declaration for the correct information.


Applicant additionally requests that all pertinent U.S. Patent and Trademark Office records relating to the subject application be changed to reflect this correction.

Applicant believes no fee is due with this request. However, if a fee is due, please charge our Deposit Account No. 50-0624, under Order No. **LUD 5684.2 CIP (10106926)** from which the undersigned is authorized to draw.

Respectfully submitted,

By James R. Crawford  
James R. Crawford  
Registration No.: 39,155  
FULBRIGHT & JAWORSKI L.L.P.  
Attorney for Applicant

666 Fifth Avenue  
New York, New York  
(212) 318-3000  
(212) 318-3400 (fax)



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
09/919,162	07/31/2001	1645	1100	LUD 5684.2 CIP (10106926)		30	4

CONFIRMATION NO. 3161

## UPDATED FILING RECEIPT



\*OC000000011470382\*

Fulbright & Jaworski LLP  
 666 Fifth Avenue  
 New York, NY 10103

Date Mailed: 12/11/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Jean-Christophe Renaud, Brussels, BELGIUM;  
 Laure Dumourjer, Brussels, BELGIUM;

*Dumourjer.*

## Domestic Priority data as claimed by applicant

This appln claims benefit of 60/245,495 11/03/2000  
 and claims benefit of 60/234,583 09/22/2000

## Foreign Applications

If Required, Foreign Filing License Granted: 08/20/2001

Projected Publication Date: 03/18/2004

Non-Publication Request: No

Early Publication Request: No

## Title

Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof

## Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**FULBRIGHT & JAWORSKI, LLP  
NEW YORK DOCKETING**

Docketed ☐ Not Required ☐

Previously ☐ Updated ☒

Docket No: NY-LUB 5684-4152-CIP

Action: \_\_\_\_\_


Reminder: \_\_\_\_\_

Date: Due/Done: \_\_\_\_\_

Initials: WJ

212 318 3111

LUD-5684.2 CIP



**DECLARATION/POWER OF ATTORNEY**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE A SOLUBLE IL-TIF RECEPTOR OR BINDING PROTEIN WHICH BINDS TO IL-TIF/IL-21, AND USES THEREOF**

the specification of which:

( ) is attached hereto.

(X) was filed on July 31, 2001 as U.S. Patent Application No. 09/919,162

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

(Number)	(Country)	(Day/Month/Year Filed)	Yes ( ) No ( ) Priority Claimed
----------	-----------	------------------------	------------------------------------

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

60/245,495  
(Application Number)

November 3, 2000  
(Filing Date)

60/234,583  
(Application Number)

September 22, 2000  
(Filing Date)

**U.S. Priority Applications**

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of the application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in

LUD-5684.2 CIP

Title 37, Code of Federal Regulations, Section §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Applic. Serial No.)	(Filing Date)	(Status patented/pending/abandoned)
(Applic. Serial No.)	(Filing Date)	(Status patented/pending/abandoned)

**Power of Attorney**

I hereby appoint the following attorneys to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: John E. Lynch, Reg. No. 20,940; Peter F. Felts, Reg. No. 20,297; Norman D. Hanson, Reg. No. 30,946; John A. Daur, Reg. No. 32,554; James Zubok, Reg. No. 38,671; James R. Crawford, Reg. No. 39,155; Andrew Im, Reg. No. 40,637, and David Rubin, Reg. No. my attorneys with full power of substitution and revocation. Address all telephone calls to James R. Crawford, (212) 318-3000. Address all correspondence to James R. Crawford, et al.

**FULBRIGHT & JAWORSKI L.L.P.**  
666 Fifth Avenue  
New York, NY 10103

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(1) Jean-Christophe Renoult

Full Name/Sole or First Inventor

Signature

Date

Residence: Avenue Hippocrate 74, UCL 74.59, B-1200 Brussels, Belgium Citizenship: Belgian

Post Office Address: Same as above

(2) Laure Dumoutier

Full Name/Sole or First Inventor

Signature

Date

Residence: Avenue Hippocrate 74, UCL 74.59, B-1200 Brussels, Belgium Citizenship: Belgian

Post Office Address: Same as above

LUD 5684.2

LUD-5684.2 CB

**DECLARATION OF ATTORNEY**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE A SOLUBLE IL-12 RECEPTOR OR BINDING PROTEIN WHICH BINDS TO IL-12/IL-23, AND USES THEREOF**

the specification of which:

- (1) is attached hereto.
- (2) was filed on July 31, 2001 as U.S. Patent Application No. 09/919,163

I hereby state that I have reviewed and understood the contents of the above identified specification, including the claims, as amended by any amendments referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(e).

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

		Yes ( ) No ( )	
(Number)	(Country)	(Day/Month/Year Filed)	Priority Claimed

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

60/245,491	November 3, 2000
(Application Number)	(Filing Date)
60/234,594	September 22, 2000
(Application Number)	(Filing Date)

**U.S. Priority Applications**

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of the application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in

623037691-1

RECEIVED TIME 18. SEP. 20:22

RECEIVED TIME 4. DEC. 18:05

LUD-5684.2 CIP

Title 37, Code of Federal Regulations, Section 51.94(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Applic. Serial No.) (Filing Date) (Status patented/pending/abandoned)

(Applic. Serial No.) (Filing Date) (Status patented/pending/abandoned)

**Power of Attorney**

I hereby appoint the following attorneys to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: John P. Lynch, Reg. No. 20,940; Peter F. Fallo, Reg. No. 20,297; Norman D. Hazzan, Reg. No. 30,946; John A. Dwyer, Reg. No. 22,554; James Zubok, Reg. No. 38,671; James R. Crawford, Reg. No. 39,155; Andrew Im, Reg. No. 40,657, and David Rabin, Reg. No. my attorneys with full power of substitution and revocation. Address all telephone calls to James R. Crawford. (212) 318-3000. Address all correspondence to James R. Crawford, at

**FULBRIGHT & JAWORSKI L.L.P.**  
666 Fifth Avenue  
New York, NY 10103

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like are made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(1) Jean-Christophe Kessels  
Full Name/Sole or First Inventor

*Renault*  
Signature

Date November 29th, 2002

Residence: Avenue Hippocrate 74, UCL 74 59, B-1200 Brussels, Belgium Citizenship: Belgian

Post Office Address: Same as above

(2) Laure Darnetier  
Full Name/Sole or First Inventor

*LDarnetier*  
Signature

*November 29th, 2002*  
Date

Residence: Avenue Hippocrate 74, UCL 74 59, B-1200 Brussels, Belgium Citizenship: Belgian

Post Office Address: Same as above

RECEIVED TIME 18 SEP. 20:22

RECEIVED TIME 4 DEC. 18:05